Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

Metastatic EGFRm NSCLC: 1L Therapy Options

University of Colorado Cancer Center

T. Patil

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

2024 ASCO® Annual Meeting Insights Hub

B. Halmos

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Total Health

J. Porter

Mediastinal Staging of Lung Cancer

MI&T Congressi

R. Trisolini

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

Insights from 2024 WCLC

S. Ikeda

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

Treatment Updates in Advanced and Metastatic NSCLC - Advances in Tho…

Total Health

J. Porter

Year in Review: Lung Cancer

Balazs Halmos

Hyperprogression in Cancer Treated With Immunotherapy

Northwestern Medicine Oncology and Hematology

Y. Chae

Year in Review 2024 - Top Clinical Trials in Neuro-Oncology

Oncology 2024 Year in Review

S. Bagley

UChicago Medicine Best of ASCO® 2024: NSCLC

UChicago Medicine Annual Practice Updates in Hematology and Oncology

R. Thawani

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

ecancer

E. Felip, A. Spira, A. Passaro, A. Addeo

World Lung Cancer Day: Key Insights and Advances in Lung Cancer Trea…

Oncology Data Advisor

S. Kareff, B. Sandy, M. Vojnic

Managing EGFR-Mutant NSCLC Patients With Osimertinib Resistance

John Conibear

Controversies in NSCLC: Neoadjuvant vs. Adjuvant IO in Early Stage D…

Luis Raez